First Images Of Key Viral Protein Could Lead To New Strategies For Human Gene Therapy

September 11, 1997

(Note: color photograph is available)

New images of an L-shaped molecule on the surface of a mouse leukemia virus could help scientists realize the promise of human gene therapy--the effort to cure disease by inserting genes directly into human cells. The images, published in the September 12 issue of Science, show the crystal structure of a piece of the virus's envelope protein--the piece required to recognize and bind to receptors on the surface of a mammalian cell.

"This is the first high-resolution structure of any retrovirus receptor-binding domain," says Dr. Peter S. Kim, a Member of the Whitehead Institute for Biomedical Research and an Associate Investigator of the Howard Hughes Medical Institute (HHMI). "Knowing the structure is critical for understanding how retroviruses bind to and enter cells and should help improve the effectiveness of human gene therapy."

Dr. Deborah Fass, first author of the Science paper and a post-doctoral fellow in Dr. James Berger's laboratory at the Whitehead Institute, explains: "Retroviruses are simultaneously a profound human medical problem and a potential medical solution. Natural retroviruses cause AIDS, leukemia, and other diseases in both humans and animals. But remodeled retroviruses, stripped of their ability to cause disease, can be ideal vehicles for gene therapy."

Retroviruses are designed by nature to transport their genetic information into the nucleus, or command center, of the cells they infect. The retrovirus DNA inserts itself into the cell's DNA where it is duplicated every time the cell divides. In a natural infection, the retrovirus DNA eventually subverts the cell's command machinery, forcing it to make thousands of new virus particles.

Almost twenty years ago, researchers discovered that they could disable some retroviruses and trick them into ferrying human genes, instead of their own genetic material, into cells. These tiny delivery vehicles, produced from a mouse leukemia virus, lack the genes required to make new virus particles. They have the potential to combat disease by inserting normal genes into tissues of patients with severe genetic diseases or cancer--a strategy called somatic cell gene therapy.

Retroviral vectors have been used in clinical trials to treat severe combined immune deficiency disease (SCID, the disease made famous by the "Bubble Boy"), and a very small number of other diseases, including several forms of cancer. Efforts to apply the technique more broadly have been limited, in part because of the inability to target retroviral vectors to specific types of cells. Ideally, if you were treating a genetic disease involving the nervous system, you would want a gene delivery vehicle that carried its cargo directly to nerve cells in the brain or spinal cord; for a muscle disorder, such as muscular dystrophy, you would want a vehicle that attached itself exclusively to muscle cells.

Researchers have not had much success targeting retroviral vectors, in part because no one knew which part of the retrovirus's envelope protein was responsible for recognizing receptors on the surface of target cells. There had to be a "key" that allowed the retrovirus to lock on to one type of cell and bypass others.

The current studies, conducted jointly by the Kim and Berger laboratories at the Whitehead Institute and by Dr. James Cunningham's HHMI laboratory at Brigham and Women's Hospital in Boston, have identified that key. On the outer surface of the retrovirus envelope protein (on the short leg of the "L" that makes up the binding domain), two helices and a series of loops fit together to form a precise pattern of ridges and valleys. This pattern is the key that determines which cells are accessible to the virus and which are not.

"By adding cell-specific hormones or other factors to the critical loops, gene therapy researchers can begin to reprogram retroviruses to bind to specific target cells," Dr. Cunningham says. "Most importantly, we can also answer fundamental questions about the role of the receptor-binding apparatus in the retrovirus life cycle."

Researchers have been trying to find the elusive receptor-binding site for more than a decade. Dr. Fass says, "The breakthrough came when Robert Davey, a post-doctoral fellow in Jim Cunningham's laboratory, purified the critical domain of the binding subunit and devised a way to obtain crystals using large quantities of the domain. By optimizing the conditions for crystal formation, we were able to solve the structure at high resolution using X-ray crystallography."

This research collaboration was supported by the Howard Hughes Medical Institute. The X-ray crystallography studies were conducted in the W.M. Keck Foundation X-ray Crystallography Suite at the Whitehead Institute.

--------

This report is based on the article "Structure of a Murine Leukemia Virus Receptor-Binding Glycoprotein at 2.0 A Resolution," in the September 12, 1997 issue of Science (277:1662-1666).

The authors are:
Dr. Deborah Fass, post-doctoral fellow in Dr. James M. Berger's laboratory at the Whitehead Institute for Biomedical Research
Dr. Robert A. Davey, post-doctoral fellow in Dr. James M. Cunningham's laboratory at the Howard Hughes Medical Institute, Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School
Mr. Christian A. Hamson, technician in the Cunningham laboratory at Brigham and Women's Hospital
Dr. Peter S. Kim, Member of the Whitehead Institute for Biomedical Research, Associate Investigator of the Howard Hughes Medical Institute, and Professor of Biology at the Massachusetts Institute of Technology
Dr. James M. Cunningham, Associate Professor of Medicine in the Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Havard Medical School, and Assistant Investigator of the Howard Hughes Medical Institute
Dr. James M. Berger, Whitehead Fellow, Whitehead Institute for Biomedical Research

Whitehead Institute for Biomedical Research

Related Leukemia Articles from Brightsurf:

New therapeutic approach against leukemia
Using an RNA molecule complex, researchers can prevent retention of cancer stem cell in their tumor supporting niche

Nanoparticle for overcoming leukemia treatment resistance
One of the largest problems with cancer treatment is the development of resistance to anticancer therapies.

Key gene in leukemia discovered
Acute myeloid leukemia (AML) is one of the most common forms of blood cancer among adults and is associated with a low survival rate, and leads to the inhibition of normal blood formation.

Vitamin B6, leukemia's deadly addiction
Researchers from CSHL and Memorial Sloan Kettering Cancer Center have discovered how Acute Myeloid Leukemia is addicted to vitamin B6.

Artificial intelligence tracks down leukemia
Artificial intelligence can detect one of the most common forms of blood cancer - acute myeloid leukemia -- with high reliability.

Milestone reached in new leukemia drug
Using a chemical compound called YKL-05-099, a team of cancer researchers from CSHL and the Dana Farber Institute was able to target the Salt-Inducible Kinase 3 (SIK3) pathway and extend survival in mice with MLL leukemia.

The drug combination effective against bovine leukemia
Scientists have succeeded in reducing levels of the bovine leukemia virus (BLV) in cows with severe infections by combining an immune checkpoint inhibitor and an enzyme inhibitor.

Towards a safer treatment for leukemia
An international team of researchers at VIB-KU Leuven, Belgium, the UK Dementia Institute and the Children's Cancer Institute, Australia, have found a safer treatment for a specific type of leukemia.

Research paves way for new source for leukemia drug
Chemistry researchers have patented a method for making anti-leukemia compounds that until now have only been available via an Asian tree that produces them.

An atlas of an aggressive leukemia
A team of researchers led by Bradley Bernstein at the Ludwig Center at Harvard has used single-cell technologies and machine learning to create a detailed 'atlas of cell states' for acute myeloid leukemia (AML) that could help improve treatment of the aggressive cancer.

Read More: Leukemia News and Leukemia Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.